Caterina Peraldo‐Neia

Fondazione Edo ed Elvo Tempia — Italy

Medicine · Health Sciences

16h-index954citations77works3.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(58), Pancreatic and Hepatic Oncology Research(26), Cancer Mechanisms and Therapy(20), Colorectal Cancer Treatments and Studies(13), MicroRNA in disease regulation(9)

Publications77 total

Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening
Journal of Translational Medicine·2025· 1 citedOpen Access
Integrating anamnestic and lifestyle data with sphingolipid levels for risk-based prostate cancer screening
2025Open Access
Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
Cancers·2025· 3 citedOpen Access
Ganglioside <scp>GD2</scp> Contributes to a Stem‐Like Phenotype in Intrahepatic Cholangiocarcinoma
Liver International·2024· 2 citedOpen Access
Altered fatty acid metabolism rewires cholangiocarcinoma stemness features
JHEP Reports·2024· 9 citedOpen Access
Structure-guided optimization of 3-hydroxybenzoisoxazole derivatives as inhibitors of Aldo-keto reductase 1C3 (AKR1C3) to target prostate cancer
European Journal of Medicinal Chemistry·2024· 9 citedOpen Access
Role of ganglioside GD2 in the stem-like compartment of intrahepatic cholangiocarcinoma
Digestive and Liver Disease·2024
Development and validation of a clinical decision support system based on PSA, microRNAs, and MRI for the detection of prostate cancer
European Radiology·2024· 2 citedOpen Access
Altered fatty acid metabolism rewires cholangiocarcinoma stemness features
Digestive and Liver Disease·2023· 1 cited
Supplementary Figure 5 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 2 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 1 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Table 1 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Data from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 2 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 6 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 3 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure Legend from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Figure 5 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
Supplementary Table 1 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Giuliana Cavalloni(36), Massimo Aglietta(35), Francesco Leone(30), Giovanna Chiorino(18), Chiara Raggi(13), Paola Ostano(13), Ivana Sarotto(11), Giorgia Migliardi(10), Serena Marchiò(9), Marco Soster(8), Loretta Gammaitoni(7), Maurizia Mello‐Grand(6), Chiara Varamo(6), Mirella Pastore(6), Benedetta Piombanti(6), Fabio Marra(6), Francesco Sassi(6), Marco Basiricò(6), Filippo Montemurro(5), Annamaria Massa(5)